Over the last decade, successful partnerships, from pre-clinical through commercial, have been one of the main contributors to our position as specialists in brain diseases and experts in neuroscience research. The importance of partnerships is recognized throughout the organization, and we strive to continuously be the partner of choice.
Why partner with Lundbeck?
1. Fully integrated company
Lundbeck is a fully integrated company with approximately 5,000 employees in more than 50 countries; we have core competencies in research, development, manufacturing, marketing and sales. Partnered products have been successfully integrated into our value chain – from pre-clinical to marketed products.
2. Proven track record of developing products for the market
The majority of Lundbeck’s currently marketed products are based on successful internal innovations and external preclinical and clinical opportunities. As a result, we are currently undertaking major launch efforts, making products such as Abilify Maintena®, Brintellix® and Rexulti® available to people with brain diseases worldwide.
The success of our products, moving through the process of being a molecule in our pipeline to being a safe product ready to be marketed, is due to our approximately 800 dedicated employees in research and development, who are entirely focused on psychiatry and neurology.
3. Proven track record of commercial success
Thanks to Lundbeck’s strong platform and global presence, we have created commercial successes for our products. In various countries worldwide, we market pharmaceuticals for the treatment of many diseases of the brain.
This success is built on a large global infrastructure for sales and marketing, with approximately 2,900 employees and strong regional commercial capabilities. Our committed commercial organization is dedicated to bringing therapies to the patients that need them.
4. Dedicated to brain diseases
Building on our own innovations and external licensing agreements, Lundbeck has more than 70 years’ experience within neuroscience research. Our R&D and commercial teams are dedicated to brain diseases, and we have a strong network among key opinion leaders and specialists in psychiatry and neurology, as well as among GPs.
Our strategy is to expand and invest to grow. We will build on our heritage and neuroscience expertise, expand our scope in brain disease and accelerate innovation to grow Lundbeck. By accelerating our efforts seeking external innovation to supplement our own, we will replenish our pipeline and create transforming therapies and a sustained flow of commercial opportunities. Brain diseases are among the greatest global burdens of disease: the patient population is expected to increase over the coming years and the unmet medical need in this area is substantial.
5. Flexible, fast decision making on partnerships
Lundbeck’s top management is committed to evaluating partnerships and has designed a process to ensure structured and fast decision making when evaluating new partnering opportunities.